Skip to content

Randomized Non-inferiority Within-Patient Trial of Density Gradient Processing of Sequential Ejaculates Versus Centrifugation-free Sperm Separation Device for ICSI in Men With Elevated Sperm DNA Fragmentation.

Randomized Non-inferiority Within-Patient Trial of Density Gradient Processing of Sequential Ejaculates Versus Centrifugation-free Sperm Separation Device for ICSI in Men With Elevated Sperm DNA Fragmentation.

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07626359
Acronym
SE
Enrollment
830
Registered
2026-06-04
Start date
2026-08-05
Completion date
2028-03-25
Last updated
2026-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Male

Keywords

pregnancy rate, Second Ejaculate, Abstinence, Microfluidic, CA0

Brief summary

Elevated SDF can adversely impact fertilization, embryo development, and pregnancy outcomes in IVF-ICSI cycles. Two pragmatic strategies aim to reduce SDF on the day of ICSI: (i) obtaining a second ejaculate shortly after the first to reduce oxidative damage and transit time; and (ii) selecting sperm via centrifugation-free sperm separation device, which enriches for motile sperm with intact DNA. There are limited direct comparisons between these strategies; this study addresses that gap.

Interventions

PROCEDUREProcessed using density gradient centrifugation

Processed using density gradient centrifugation

PROCEDURESecond Ejaculate (collected after 1-3 hours)

The second ejaculate will be processed with two-layer density gradient centrifugation followed by standard washing.

Sponsors

Indira IVF Hospital Pvt Ltd
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* • Elevated SDF defined as DFI \>20 %measured by the sperm chromatin dispersion (SCD) test performed in a participating center's andrology laboratory, using a harmonized protocol under standardized conditions after 2-3 days of ejaculatory abstinence, and within 90 days (≤3 months) prior to enrollment. * Male partners 21-45 years; * Female partners 21-35 years. * Undergoing IVF/ICSI. * No known genetic or chromosomal abnormalities. * Minimum 4 MII oocyte patients shall be included

Exclusion criteria

* Azoospermia or severe oligoasthenozoospermia (\<1 million motile sperm/mL). * Significant systemic disease (e.g., uncontrolled diabetes, malignancy). * History of a prior ICSI cycle with no embryo development. * Relevant female factors: untreated adnexal pathology ,a history of a thin endometrium (\<7 mm) following endometrium preparation for embryo transfer

Design outcomes

Primary

MeasureTime frameDescription
Ongoing Pregnancy Rate12 weeks of gestationOngoing pregnancy rate

Secondary

MeasureTime frameDescription
Sperm motility and morphology after sperm sorting or second ejaculate collection.At the day of ICSISperm motility and morphology after sperm sorting or second ejaculate collection.
Blastocyst rateDay 5&6 after ICSIBlastocyst rate
Good Blastocyst rateDay 5&6 after ICSITotal number of good blast
Biochemical Pregnancy Rate2 weeks after embryo transferBiochemical Pregnancy Rate
Implantation Rate4-6 weeks after embryo transferAn embryo implantation rate is the percentage of transferred embryos that successfully attach to the uterine lining and develop into a clinical pregnancy
Clinical Pregnancy Rate4-6 weeks after embryo transfermeasures the percentage of fertility treatment cycles (like IVF) that result in a pregnancy confirmed by an ultrasound showing a gestational sac or fetal heartbeat
First trimester Miscarriage RateTill 12 weeks after embryo transferMiscarriages are very common, occurring in about 10% to 20% of all known pregnancies.

Countries

India

Contacts

CONTACTShashank Sanagoudar, MS
drsanagoudar@gmail.com91-8050406053
CONTACTSandro Esteves, PhD
s.esteves@androfert.com.br
PRINCIPAL_INVESTIGATORVipin Chandra, DGO

Indira IVF Hospital Limited

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 5, 2026